{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:31Z","timestamp":1791855811789,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00467-025-07033-4","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:28:58Z","timestamp":1763141338000},"page":"1685-1692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-2659","authenticated-orcid":false,"given":"Cyrielle","family":"Parmentier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Lise","family":"Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Diep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Ulinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"7033_CR1","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014090915","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A et al (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266. https:\/\/doi.org\/10.1681\/ASN.2014090915","journal-title":"J Am Soc Nephrol"},{"key":"7033_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.0432","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.0432","journal-title":"JAMA Pediatr"},{"key":"7033_CR3","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s00467-022-05508-7","volume":"37","author":"G Mathew","year":"2022","unstructured":"Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, Bagga A (2022) Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatr Nephrol 37:3117\u20133126. https:\/\/doi.org\/10.1007\/s00467-022-05508-7","journal-title":"Pediatr Nephrol"},{"key":"7033_CR4","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1054\/bjoc.2001.2116","volume":"85","author":"PW Johnson","year":"2001","unstructured":"Johnson PW, Glennie MJ (2001) Rituximab: mechanisms and applications. Br J Cancer 85:1619\u20131623. https:\/\/doi.org\/10.1054\/bjoc.2001.2116","journal-title":"Br J Cancer"},{"key":"7033_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.55563\/clinexprheumato.4123","volume":"40","author":"I Oomen","year":"2022","unstructured":"Oomen I, Nassar-Sheikh Rashid A, Bouts AHM, Gouw SC, Kuijpers TW, Rispens T, de Vries A, Wolbink G, van den Berg JM, Schonenberg-Meinema D (2022) Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases. Clin Exp Rheumatol 40:183\u2013190. https:\/\/doi.org\/10.55563\/clinexprheumato.4123","journal-title":"Clin Exp Rheumatol"},{"key":"7033_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/1078-0432.CCR-10-1684","volume":"17","author":"G Cartron","year":"2011","unstructured":"Cartron G, Trappe RU, Solal-C\u00e9ligny P, Hallek M (2011) Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 17:19\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1684","journal-title":"Clin Cancer Res"},{"key":"7033_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.0000000000000122","volume":"18","author":"M Teisseyre","year":"2023","unstructured":"Teisseyre M, Brglez V, Cremoni M, Fernandez C, Gra\u00e7a D, Boyer-Suavet S, Benzaken S, Esnault VLM, Seitz-Polski B (2023) Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy. Clin J Am Soc Nephrol 18:785\u2013787. https:\/\/doi.org\/10.2215\/CJN.0000000000000122","journal-title":"Clin J Am Soc Nephrol"},{"key":"7033_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard.2008.105379","volume":"69","author":"RM Thurlings","year":"2010","unstructured":"Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ (2010) Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69:409\u2013412. https:\/\/doi.org\/10.1136\/ard.2008.105379","journal-title":"Ann Rheum Dis"},{"key":"7033_CR9","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/rheumatology\/keac127","volume":"61","author":"VR Reddy","year":"2022","unstructured":"Reddy VR, Pepper RJ, Shah K et al (2022) Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? Rheumatology 61:2894\u20132904. https:\/\/doi.org\/10.1093\/rheumatology\/keac127","journal-title":"Rheumatology"},{"key":"7033_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00467-021-05207-1","volume":"37","author":"Q Bertrand","year":"2022","unstructured":"Bertrand Q, Mignot S, Kwon T et al (2022) Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome. Pediatr Nephrol 37:357\u2013365. https:\/\/doi.org\/10.1007\/s00467-021-05207-1","journal-title":"Pediatr Nephrol"},{"key":"7033_CR11","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00467-020-04611-8","volume":"35","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Nishino T, Endo S, Umeda C, Watanabe Y, Nakagawa M (2020) Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:2003\u20132008. https:\/\/doi.org\/10.1007\/s00467-020-04611-8","journal-title":"Pediatr Nephrol"},{"key":"7033_CR12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.41587","volume":"73","author":"AD Marinov","year":"2021","unstructured":"Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, Perro M, Klein C, Nickerson KM, Shlomchik MJ (2021) The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol 73:826\u2013836. https:\/\/doi.org\/10.1002\/art.41587","journal-title":"Arthritis Rheumatol"},{"key":"7033_CR13","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1007\/s00467-025-06703-7","volume":"40","author":"S Fujinaga","year":"2025","unstructured":"Fujinaga S, Saito K, Watanabe Y, Nakagawa M, Sakuraya K (2025) Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies. Pediatr Nephrol 40:2493\u20132495. https:\/\/doi.org\/10.1007\/s00467-025-06703-7","journal-title":"Pediatr Nephrol"},{"key":"7033_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-024-06621-7","volume":"40","author":"EY-H Chan","year":"2025","unstructured":"Chan EY-H, Lin KY-K, Yap DY-H, Ma AL-T (2025) Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion. Pediatr Nephrol 40:711\u2013714. https:\/\/doi.org\/10.1007\/s00467-024-06621-7","journal-title":"Pediatr Nephrol"},{"key":"7033_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14010239","volume":"14","author":"M Drozynska-Duklas","year":"2025","unstructured":"Drozynska-Duklas M, Kranz A, Zagozdzon I, Balasz-Chmielewska I, Chudzik I, Zurowska A (2025) Successful switch to obinutuzumab in a rituximab-intolerant child with difficult-to-treat idiopathic nephrotic syndrome. J Clin Med 14:239. https:\/\/doi.org\/10.3390\/jcm14010239","journal-title":"J Clin Med"},{"key":"7033_CR16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J (2023) Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children. Clin J Am Soc Nephrol 18:1555\u20131562. https:\/\/doi.org\/10.2215\/CJN.0000000000000288","journal-title":"Clin J Am Soc Nephrol"},{"key":"7033_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05835-2","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E et al (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05835-2","journal-title":"Pediatr Nephrol"},{"key":"7033_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.ekir.2022.09.018","volume":"7","author":"A Angeletti","year":"2022","unstructured":"Angeletti A, Bruschi M, Colucci M et al (2022) Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome. Kidney Int Rep 7:2509\u20132512. https:\/\/doi.org\/10.1016\/j.ekir.2022.09.018","journal-title":"Kidney Int Rep"},{"key":"7033_CR19","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393\u20134402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979","journal-title":"Blood"},{"key":"7033_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4049\/jimmunol.2300376","volume":"212","author":"T Rispens","year":"2024","unstructured":"Rispens T, Kuijpers TW, Killestein J, van Kempen ZLE, Bloem K (2024) Cross-reactivity of antibodies to rituximab with other therapeutic anti-CD20 antibodies. J Immunol 212:529\u2013533. https:\/\/doi.org\/10.4049\/jimmunol.2300376","journal-title":"J Immunol"},{"key":"7033_CR21","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/rheumatology\/kead168","volume":"62","author":"C Wincup","year":"2023","unstructured":"Wincup C, Dunn N, Ruetsch-Chelli C et al (2023) Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus. Rheumatology 62:2601\u20132610. https:\/\/doi.org\/10.1093\/rheumatology\/kead168","journal-title":"Rheumatology"},{"key":"7033_CR22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00467-017-3835-7","volume":"33","author":"K Kamei","year":"2018","unstructured":"Kamei K, Ogura M, Sato M, Ito S, Ishikura K (2018) Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. Pediatr Nephrol 33:1013\u20131018. https:\/\/doi.org\/10.1007\/s00467-017-3835-7","journal-title":"Pediatr Nephrol"},{"key":"7033_CR23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bcp.13552","volume":"84","author":"A Bonanni","year":"2018","unstructured":"Bonanni A, Calatroni M, D\u2019Alessandro M et al (2018) Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol 84:1238\u20131249. https:\/\/doi.org\/10.1111\/bcp.13552","journal-title":"Br J Clin Pharmacol"},{"key":"7033_CR24","doi-asserted-by":"publisher","unstructured":"Wincup C, Menon M, Smith E, Schwartz A, Isenberg D, Jury EC, Mauri C; ABIRISK Consortium (2019) Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. Ann Rheum Dis 78:1140\u20131142. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214779","DOI":"10.1136\/annrheumdis-2018-214779"},{"key":"7033_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572863","volume":"11","author":"GE Fouda","year":"2020","unstructured":"Fouda GE, Bavbek S (2020) Rituximab hypersensitivity: from clinical presentation to management. Front Pharmacol 11:572863. https:\/\/doi.org\/10.3389\/fphar.2020.572863","journal-title":"Front Pharmacol"},{"key":"7033_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-021-02536-5","volume":"23","author":"F Faustini","year":"2021","unstructured":"Faustini F, Dunn N, Kharlamova N, Ryner M, Bruchfeld A, Malmstr\u00f6m V, Fogdell-Hahn A, Gunnarsson I (2021) First exposure to rituximab is associated with high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis. Arthritis Res Ther 23:211. https:\/\/doi.org\/10.1186\/s13075-021-02536-5","journal-title":"Arthritis Res Ther"},{"key":"7033_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.07.004","volume":"67","author":"G Bayer","year":"2019","unstructured":"Bayer G, Agier M-S, Lioger B, Lepelley M, Zenut M, Lanoue M-C, Maillot F, Jonville-Bera A-P (2019) Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med 67:59\u201364. https:\/\/doi.org\/10.1016\/j.ejim.2019.07.004","journal-title":"Eur J Intern Med"},{"key":"7033_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.007","volume":"45","author":"P Karmacharya","year":"2015","unstructured":"Karmacharya P, Poudel DR, Pathak R, Donato AA, Ghimire S, Giri S, Aryal MR, Bingham CO (2015) Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum 45:334\u2013340. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.007","journal-title":"Semin Arthritis Rheum"},{"key":"7033_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.6004\/jadpro.2024.15.5.6","volume":"15","author":"EH Zacholski","year":"2024","unstructured":"Zacholski EH, Rugh S, Marshall J, Nadpara P, Moore D (2024) Obinutuzumab infusion-related reactions: multicenter retrospective evaluation of incidence, severity, and risk factors. J Adv Pract Oncol 15:437\u2013443. https:\/\/doi.org\/10.6004\/jadpro.2024.15.5.6","journal-title":"J Adv Pract Oncol"},{"key":"7033_CR30","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1093\/rheumatology\/keac209","volume":"61","author":"J Arnold","year":"2022","unstructured":"Arnold J, Dass S, Twigg S et al (2022) Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Rheumatology 61:4905\u20134909. https:\/\/doi.org\/10.1093\/rheumatology\/keac209","journal-title":"Rheumatology"},{"key":"7033_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ctrv.2015.09.004","volume":"41","author":"T Illidge","year":"2015","unstructured":"Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G (2015) Obinutuzumab in hematologic malignancies: lessons learned to date. Cancer Treat Rev 41:784\u2013792. https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.004","journal-title":"Cancer Treat Rev"},{"key":"7033_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859419","volume":"13","author":"M Teisseyre","year":"2022","unstructured":"Teisseyre M, Cremoni M, Boyer-Suavet S, Ruetsch C, Gra\u00e7a D, Esnault VLM, Brglez V, Seitz-Polski B (2022) Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy. Front Immunol 13:859419. https:\/\/doi.org\/10.3389\/fimmu.2022.859419","journal-title":"Front Immunol"},{"key":"7033_CR33","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00467-022-05540-4","volume":"37","author":"S Fujinaga","year":"2022","unstructured":"Fujinaga S, Endo S (2022) Anti-B cell strategy for complicated steroid-dependent nephrotic syndrome in children with anti-rituximab antibodies. Pediatr Nephrol 37:2521\u20132522. https:\/\/doi.org\/10.1007\/s00467-022-05540-4","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07033-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07033-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07033-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:52:35Z","timestamp":1777902755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07033-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7033"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07033-4","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no relevant financial or non-financial conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}